Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects.

Darpo B, Xue H, Tanaka SK, Tzanis E.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00922-19. doi: 10.1128/AAC.00922-19. Print 2019 Oct.

2.

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01135-17. doi: 10.1128/AAC.01135-17. Print 2017 Sep.

3.

In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis.

Steenbergen J, Tanaka SK, Miller LL, Halasohoris SA, Hershfield JR.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02434-16. doi: 10.1128/AAC.02434-16. Print 2017 May.

4.

Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.

Lin W, Flarakos J, Du Y, Hu W, He H, Mangold J, Tanaka SK, Villano S.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01784-16. doi: 10.1128/AAC.01784-16. Print 2017 Jan.

5.

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.

Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, Sunkara G, Kovacs SJ, Villano S, Tanaka SK.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7431-7435. Print 2016 Dec.

6.

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants.

Tzanis E, Manley A, Villano S, Tanaka SK, Bai S, Loh E.

J Clin Pharmacol. 2017 Mar;57(3):321-327. doi: 10.1002/jcph.814. Epub 2016 Sep 22.

7.

Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.

Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, Zhu B, Alexander N, Natrillo A, Hanna I, Ting L, Zhou W, Dole K, Sun H, Kovacs SJ, Stein DS, Tanaka SK, Villano S, Mangold JB.

Xenobiotica. 2017 Aug;47(8):682-696. doi: 10.1080/00498254.2016.1213465. Epub 2016 Aug 8.

PMID:
27499331
8.

Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.

Tanaka SK, Steenbergen J, Villano S.

Bioorg Med Chem. 2016 Dec 15;24(24):6409-6419. doi: 10.1016/j.bmc.2016.07.029. Epub 2016 Jul 18. Review.

9.

In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline.

Tanaka SK, Villano S.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5247-53. doi: 10.1128/AAC.00320-16. Print 2016 Sep.

10.

Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.

Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, Mechiche R, Ohemeng K, Verma AK, Cannon EP, Macone A, Tanaka SK, Levy S.

Antimicrob Agents Chemother. 2015 Nov;59(11):7044-53. doi: 10.1128/AAC.01536-15. Epub 2015 Sep 8.

11.

Factors affecting medication adherence trajectories for patients with heart failure.

Juarez DT, Williams AE, Chen C, Daida YG, Tanaka SK, Trinacty CM, Vogt TM.

Am J Manag Care. 2015 Mar 1;21(3):e197-205.

12.

Anatomic course of the medial antebrachial cutaneous nerve: a cadaveric study with proposed clinical application in failed cubital tunnel release.

Tanaka SK, Lourie GM.

J Hand Surg Eur Vol. 2015 Feb;40(2):210-2. doi: 10.1177/1753193413515826. Epub 2013 Dec 11. No abstract available.

PMID:
24334556
13.

In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.

Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB.

Antimicrob Agents Chemother. 2014;58(2):1127-35. doi: 10.1128/AAC.01242-13. Epub 2013 Dec 2.

14.

Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.

Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, Levy SB.

Antimicrob Agents Chemother. 2014;58(3):1279-83. doi: 10.1128/AAC.01066-13. Epub 2013 Sep 16.

15.

A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.

Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD.

Antimicrob Agents Chemother. 2012 Nov;56(11):5650-4. doi: 10.1128/AAC.00948-12. Epub 2012 Aug 20.

16.

Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.

Garrity-Ryan LK, Kim OK, Balada-Llasat JM, Bartlett VJ, Verma AK, Fisher ML, Castillo C, Songsungthong W, Tanaka SK, Levy SB, Mecsas J, Alekshun MN.

Infect Immun. 2010 Nov;78(11):4683-90. doi: 10.1128/IAI.01305-09. Epub 2010 Sep 7.

17.

N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability.

Grier MC, Garrity-Ryan LK, Bartlett VJ, Klausner KA, Donovan PJ, Dudley C, Alekshun MN, Tanaka SK, Draper MP, Levy SB, Kim OK.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3380-3. doi: 10.1016/j.bmcl.2010.04.014. Epub 2010 Apr 11.

PMID:
20434913
18.

N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents.

Kim OK, Garrity-Ryan LK, Bartlett VJ, Grier MC, Verma AK, Medjanis G, Donatelli JE, Macone AB, Tanaka SK, Levy SB, Alekshun MN.

J Med Chem. 2009 Sep 24;52(18):5626-34. doi: 10.1021/jm9006577.

19.

MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis.

Casaz P, Garrity-Ryan LK, McKenney D, Jackson C, Levy SB, Tanaka SK, Alekshun MN.

Microbiology. 2006 Dec;152(Pt 12):3643-50.

PMID:
17159217
20.

A case of cerebral sinus thrombosis developed during a high-altitude expedition to Gasherbrum I.

Saito S, Tanaka SK.

Wilderness Environ Med. 2003 Winter;14(4):226-30.

PMID:
14719856
21.

Antimicrobial effects of novel siderophores linked to beta-lactam antibiotics.

Kline T, Fromhold M, McKennon TE, Cai S, Treiberg J, Ihle N, Sherman D, Schwan W, Hickey MJ, Warrener P, Witte PR, Brody LL, Goltry L, Barker LM, Anderson SU, Tanaka SK, Shawar RM, Nguyen LY, Langhorne M, Bigelow A, Embuscado L, Naeemi E.

Bioorg Med Chem. 2000 Jan;8(1):73-93.

PMID:
10968267
22.

Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK.

Antimicrob Agents Chemother. 1999 Dec;43(12):2877-80.

23.

Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection.

Alder JD, Ewing PJ, Nilius AM, Mitten M, Tovcimak A, Oleksijew A, Jarvis K, Paige L, Tanaka SK.

Antimicrob Agents Chemother. 1998 Sep;42(9):2385-90.

24.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY.

J Antimicrob Chemother. 1997 Aug;40(2):283-6.

PMID:
9301997
25.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

Stone GG, Shortridge D, Flamm RK, Beyer J, Ghoneim AT, Tanaka SK.

J Antimicrob Chemother. 1997 Aug;40(2):251-6.

PMID:
9301991
26.

Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.

Nilius AM, Beyer JM, Flamm RK, Tanaka SK.

J Clin Microbiol. 1997 Jun;35(6):1311-5.

27.

PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin.

Stone GG, Shortridge D, Flamm RK, Beyer J, Stamler D, Tanaka SK.

Epidemiol Infect. 1997 Apr;118(2):119-24.

28.

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Versalovic J, Beyer J, Flamm RK, Graham DY, Ghoneim AT, Tanaka SK.

Antimicrob Agents Chemother. 1997 Mar;41(3):712-4.

29.

Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.

Shortridge VD, Stone GG, Flamm RK, Beyer J, Versalovic J, Graham DW, Tanaka SK.

J Clin Microbiol. 1997 Feb;35(2):471-3. Erratum in: J Clin Microbiol 1998 May;36(5):1468.

30.

Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, Zulawinski L, Tanaka SK.

Helicobacter. 1996 Dec;1(4):227-8.

PMID:
9432314
31.

Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies.

Alder JD, Ewing PJ, Mitten MJ, Oleksijew A, Tanaka SK.

Am J Gastroenterol. 1996 Nov;91(11):2347-54.

PMID:
8931416
32.

Novel mechanism of macrolide resistance in Streptococcus pneumoniae.

Shortridge VD, Flamm RK, Ramer N, Beyer J, Tanaka SK.

Diagn Microbiol Infect Dis. 1996 Oct;26(2):73-8.

PMID:
8985659
33.

Kill kinetics of antimicrobial agents against Helicobacter pylori.

Flamm RK, Beyer J, Tanaka SK, Clement J.

J Antimicrob Chemother. 1996 Oct;38(4):719-25.

PMID:
8937967
34.
35.

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF.

Antimicrob Agents Chemother. 1996 Feb;40(2):477-80.

36.

Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole.

Hachem CY, Clarridge JE, Reddy R, Flamm R, Evans DG, Tanaka SK, Graham DY.

Diagn Microbiol Infect Dis. 1996 Jan;24(1):37-41.

PMID:
8988762
37.

In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.

Flamm RK, Vojtko C, Chu DT, Li Q, Beyer J, Hensey D, Ramer N, Clement JJ, Tanaka SK.

Antimicrob Agents Chemother. 1995 Apr;39(4):964-70.

38.

In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.

Clement JJ, Tanaka SK, Alder J, Vojtko C, Beyer J, Hensey D, Ramer N, McDaniel D, Chu DT.

Antimicrob Agents Chemother. 1994 May;38(5):1071-8.

39.

Synthesis and antifungal activity of 1,3,2-benzodithiazole S-oxides.

Klein LL, Yeung CM, Weissing DE, Lartey PA, Tanaka SK, Plattner JJ, Mulford DJ.

J Med Chem. 1994 Mar 4;37(5):572-8.

PMID:
8126696
40.

New developments in macrolides: structures and antibacterial and prokinetic activities.

Lartey PA, Nellans HN, Tanaka SK.

Adv Pharmacol. 1994;28:307-43. Review. No abstract available.

PMID:
8080820
41.

Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents.

Chu DT, Hallas R, Tanaka SK, Alder J, Balli D, Plattner JJ.

Drugs Exp Clin Res. 1994;20(5):177-83.

PMID:
7875053
42.

Calbistrins, novel antifungal agents produced by Penicillium restrictum. I. Production, taxonomy of the producing organism and biological activity.

Jackson M, Karwowski JP, Humphrey PE, Kohl WL, Barlow GJ, Tanaka SK.

J Antibiot (Tokyo). 1993 Jan;46(1):34-8.

43.

Inactivation of beta-lactamases from Enterobacter cloacae by monophosphams.

Bush K, Smith SA, Tanaka SK, Bonner DP.

J Antimicrob Chemother. 1988 Dec;22(6):801-9.

PMID:
3266620
44.

Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties.

Bonner DP, O'Sullivan J, Tanaka SK, Clark JM, Whitney RR.

J Antibiot (Tokyo). 1988 Dec;41(12):1745-51.

45.

Xylocandin: a new complex of antifungal peptides. I. Taxonomy, isolation and biological activity.

Meyers E, Bisacchi GS, Dean L, Liu WC, Minassian B, Slusarchyk DS, Sykes RB, Tanaka SK, Trejo W.

J Antibiot (Tokyo). 1987 Nov;40(11):1515-9.

46.

Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli.

Bush K, Smith SA, Ohringer S, Tanaka SK, Bonner DP.

Antimicrob Agents Chemother. 1987 Aug;31(8):1271-3.

47.

In vitro evaluation of tigemonam, a novel oral monobactam.

Tanaka SK, Summerill RA, Minassian BF, Bush K, Visnic DA, Bonner DP, Sykes RB.

Antimicrob Agents Chemother. 1987 Feb;31(2):219-25.

48.

Aztreonam: preclinical studies.

Bonner DP, Tanaka SK, Schwind RA.

N J Med. 1986 Jan;Spec No:20-5. No abstract available.

PMID:
3456495
49.

Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae.

Bush K, Tanaka SK, Bonner DP, Sykes RB.

Antimicrob Agents Chemother. 1985 Apr;27(4):555-60.

50.

[Rehabilitation and nursing care of the patient with apoplexy].

Tanaka SK, Takahshi M, Abe J, Nakada R.

Kango Gijutsu. 1969 Jun:42-9. Japanese. No abstract available.

PMID:
5194072

Supplemental Content

Loading ...
Support Center